Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
104.17 USD | -0.40% |
|
+7.77% | +50.88% |
16/07 | Insmed Insider Sold Shares Worth $699,220, According to a Recent SEC Filing | MT |
10/07 | Insmed Insider Sold Shares Worth $5,537,460, According to a Recent SEC Filing | MT |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -21.55 | -22.5 | -20.61 | -28.5 | -29.31 | |||||
Return on Total Capital | -24.75 | -26.94 | -24.53 | -34.87 | -37.49 | |||||
Return On Equity % | -109.42 | -126.66 | -193.22 | 614.47 | 3.93T | |||||
Return on Common Equity | -109.42 | -126.66 | -193.22 | 614.47 | 3.93T | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 20.6 | 76.57 | 77.53 | 78.52 | 76.43 | |||||
SG&A Margin | 123.84 | 123.99 | 108.32 | 112.87 | 126.78 | |||||
EBITDA Margin % | -155.01 | -189.3 | -191.84 | -220.34 | -213.82 | |||||
EBITA Margin % | -161.23 | -194.71 | -194.79 | -223.04 | -216.21 | |||||
EBIT Margin % | -161.32 | -194.82 | -194.87 | -223.1 | -216.26 | |||||
Income From Continuing Operations Margin % | -178.87 | -230.63 | -196.26 | -245.59 | -251.24 | |||||
Net Income Margin % | -178.87 | -230.63 | -196.26 | -245.59 | -251.24 | |||||
Net Avail. For Common Margin % | -178.87 | -230.63 | -196.26 | -245.59 | -251.24 | |||||
Normalized Net Income Margin | -111.26 | -136.23 | -127.61 | -147.1 | -140.63 | |||||
Levered Free Cash Flow Margin | -65.2 | -95.4 | -80.97 | -126.14 | -115.01 | |||||
Unlevered Free Cash Flow Margin | -66.36 | -98.44 | -75.48 | -111.87 | -102.27 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.21 | 0.18 | 0.17 | 0.2 | 0.22 | |||||
Fixed Assets Turnover | 1.56 | 1.96 | 2.48 | 2.96 | 3.31 | |||||
Receivables Turnover (Average Receivables) | 9.19 | 9.21 | 9.08 | 8.61 | 7.8 | |||||
Inventory Turnover (Average Inventory) | 3.35 | 0.76 | 0.81 | 0.86 | 0.94 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.24 | 6.19 | 6.69 | 4.12 | 5.45 | |||||
Quick Ratio | 4.62 | 5.48 | 6.19 | 3.64 | 4.99 | |||||
Operating Cash Flow to Current Liabilities | -1.85 | -2.69 | -2.1 | -2.38 | -2.3 | |||||
Days Sales Outstanding (Average Receivables) | 39.84 | 39.62 | 40.21 | 42.4 | 46.89 | |||||
Days Outstanding Inventory (Average Inventory) | 109.2 | 481.96 | 453.32 | 426.3 | 388.07 | |||||
Average Days Payable Outstanding | 67.54 | 233.09 | 271.19 | 267.98 | 250.63 | |||||
Cash Conversion Cycle (Average Days) | 81.5 | 288.49 | 222.34 | 200.71 | 184.33 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 146.74 | 149.16 | 1.51T | -409.44 | 459.02 | |||||
Total Debt / Total Capital | 59.47 | 59.87 | 93.78 | 132.32 | 82.11 | |||||
LT Debt/Equity | 142.19 | 146.69 | 1.5T | -406.23 | 454.7 | |||||
Long-Term Debt / Total Capital | 57.63 | 58.87 | 93.2 | 131.28 | 81.34 | |||||
Total Liabilities / Total Assets | 65.35 | 66.99 | 94.69 | 124.96 | 85.91 | |||||
EBIT / Interest Expense | -8.97 | -9.07 | -17.09 | -8.37 | -9.24 | |||||
EBITDA / Interest Expense | -7.99 | -8.34 | -15.96 | -7.96 | -8.71 | |||||
(EBITDA - Capex) / Interest Expense | -8.2 | -8.52 | -16.32 | -8.13 | -8.97 | |||||
Total Debt / EBITDA | -1.71 | -1.81 | -2.97 | -2.1 | -1.77 | |||||
Net Debt / EBITDA | 0.54 | 0.46 | -0.4 | -0.89 | 0.17 | |||||
Total Debt / (EBITDA - Capex) | -1.67 | -1.78 | -2.91 | -2.06 | -1.72 | |||||
Net Debt / (EBITDA - Capex) | 0.53 | 0.45 | -0.39 | -0.87 | 0.16 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 20.48 | 14.63 | 30.19 | 24.39 | 19.17 | |||||
Gross Profit, 1 Yr. Growth % | -39.61 | 15.87 | 31.82 | 25.97 | 16 | |||||
EBITDA, 1 Yr. Growth % | 11.02 | 39.98 | 31.94 | 42.87 | 15.64 | |||||
EBITA, 1 Yr. Growth % | 12.75 | 38.43 | 30.24 | 42.44 | 15.52 | |||||
EBIT, 1 Yr. Growth % | 12.75 | 38.43 | 30.22 | 42.42 | 15.51 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 15.63 | 47.8 | 10.79 | 55.66 | 21.91 | |||||
Net Income, 1 Yr. Growth % | 15.63 | 47.8 | 10.79 | 55.66 | 21.91 | |||||
Normalized Net Income, 1 Yr. Growth % | 15.43 | 40.35 | 21.95 | 43.39 | 13.93 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 0.1 | 28.77 | 0.87 | 36.44 | 4.31 | |||||
Accounts Receivable, 1 Yr. Growth % | -13.88 | 47.03 | 22.02 | 38.62 | 26.28 | |||||
Inventory, 1 Yr. Growth % | 75.16 | 35.12 | 4.35 | 19.06 | 18.41 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -14.04 | -1.77 | 6.87 | 2.26 | 10.73 | |||||
Total Assets, 1 Yr. Growth % | 7.26 | 56.19 | 33.21 | -19.72 | 52.29 | |||||
Tangible Book Value, 1 Yr. Growth % | 5.3 | -11.29 | -132.65 | 529.04 | -123.75 | |||||
Common Equity, 1 Yr. Growth % | 5.43 | 48.78 | -78.57 | -477.4 | -185.98 | |||||
Cash From Operations, 1 Yr. Growth % | -12.49 | 65.63 | 10.22 | 33.91 | 27.53 | |||||
Capital Expenditures, 1 Yr. Growth % | -85.24 | 16.81 | 35.52 | 34.52 | 64.98 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -46.06 | 67.7 | 10.51 | 92.51 | 8.65 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -45.67 | 70.05 | -0.18 | 83.09 | 8.94 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 308.87 | 17.52 | 22.16 | 27.26 | 21.75 | |||||
Gross Profit, 2 Yr. CAGR % | 113.74 | 13.38 | 23.59 | 28.86 | 20.88 | |||||
EBITDA, 2 Yr. CAGR % | -8.21 | 26 | 37.21 | 38.24 | 29.21 | |||||
EBITA, 2 Yr. CAGR % | -6.94 | 26.24 | 35.52 | 37.11 | 28.93 | |||||
EBIT, 2 Yr. CAGR % | -7.1 | 24.93 | 34.26 | 36.18 | 28.26 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -4.77 | 30.73 | 27.96 | 31.32 | 37.75 | |||||
Net Income, 2 Yr. CAGR % | -4.77 | 30.73 | 27.96 | 31.32 | 37.75 | |||||
Normalized Net Income, 2 Yr. CAGR % | -4.64 | 27.28 | 30.83 | 32.24 | 27.81 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -15.5 | 13.54 | 13.97 | 17.32 | 19.3 | |||||
Accounts Receivable, 2 Yr. CAGR % | 73.29 | 12.52 | 33.94 | 30.06 | 32.31 | |||||
Inventory, 2 Yr. CAGR % | 165.56 | 53.84 | 18.74 | 11.46 | 18.74 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 107.26 | -8.11 | 2.46 | 4.54 | 6.41 | |||||
Total Assets, 2 Yr. CAGR % | 14.76 | 29.43 | 44.24 | 3.41 | 10.57 | |||||
Tangible Book Value, 2 Yr. CAGR % | 15.15 | -3.35 | -46.18 | 43.3 | 22.22 | |||||
Common Equity, 2 Yr. CAGR % | 15.09 | 25.24 | -43.54 | -10.08 | 80.13 | |||||
Cash From Operations, 2 Yr. CAGR % | -7.79 | 20.39 | 35.11 | 21.49 | 30.68 | |||||
Capital Expenditures, 2 Yr. CAGR % | -30.96 | -58.47 | 25.82 | 35.02 | 48.98 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -16.59 | -4.89 | 36.16 | 45.81 | 44.63 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -16.22 | -3.88 | 30.31 | 35.19 | 41.23 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | - | 167.6 | 21.6 | 22.9 | 24.5 | |||||
Gross Profit, 3 Yr. CAGR % | - | 169.02 | 19.22 | 24.38 | 24.42 | |||||
EBITDA, 3 Yr. CAGR % | 11.07 | 5.65 | 27.95 | 39.07 | 30.26 | |||||
EBITA, 3 Yr. CAGR % | 11.95 | 6.23 | 27.56 | 37.79 | 29.5 | |||||
EBIT, 3 Yr. CAGR % | 11.97 | 6.11 | 26.67 | 36.93 | 28.91 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 15.14 | 10.26 | 23.71 | 36.6 | 28.1 | |||||
Net Income, 3 Yr. CAGR % | 15.14 | 10.26 | 23.71 | 36.6 | 28.1 | |||||
Normalized Net Income, 3 Yr. CAGR % | 14.91 | 8.47 | 25.48 | 34.89 | 25.83 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 1.36 | -2.76 | 9.15 | 21.02 | 12.81 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | 64.06 | 15.6 | 35.48 | 28.78 | |||||
Inventory, 3 Yr. CAGR % | - | 112.01 | 35.17 | 18.85 | 13.73 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 98.5 | 61.59 | -3.36 | 2.39 | 6.56 | |||||
Total Assets, 3 Yr. CAGR % | 19.89 | 27.18 | 30.68 | 18.65 | 17.65 | |||||
Tangible Book Value, 3 Yr. CAGR % | -8.8 | 5.56 | -32.69 | 22.13 | -21.29 | |||||
Common Equity, 3 Yr. CAGR % | -8.58 | 25.38 | -30.47 | 6.36 | -11.41 | |||||
Cash From Operations, 3 Yr. CAGR % | 11.18 | 12.09 | 16.9 | 34.71 | 23.47 | |||||
Capital Expenditures, 3 Yr. CAGR % | 27.64 | -17.73 | -38.4 | 28.65 | 44.35 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 6.48 | 5.28 | -0.01 | 53.16 | 32.19 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 8.31 | 6.07 | -2.66 | 46.29 | 25.8 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 98.78 | 21.66 | |||||
Gross Profit, 5 Yr. CAGR % | -7.96 | 10.58 | - | 100.41 | 19.88 | |||||
EBITDA, 5 Yr. CAGR % | 17.15 | 15.85 | 20.4 | 17.32 | 28.19 | |||||
EBITA, 5 Yr. CAGR % | 17.67 | 16.18 | 20.4 | 17.33 | 27.85 | |||||
EBIT, 5 Yr. CAGR % | 17.69 | 16.19 | 20.41 | 17.25 | 27.3 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 20 | 19.78 | 20.11 | 18.24 | 29.15 | |||||
Net Income, 5 Yr. CAGR % | 20 | 19.78 | 20.11 | 18.24 | 29.15 | |||||
Normalized Net Income, 5 Yr. CAGR % | 19.49 | 18.45 | 21.03 | 17.42 | 26.41 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 8.33 | 6.36 | 6.23 | 4.82 | 13.1 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 49.5 | 22.02 | |||||
Inventory, 5 Yr. CAGR % | - | - | - | 63.93 | 28.34 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 64.42 | 56.98 | 52.36 | 35.76 | 0.43 | |||||
Total Assets, 5 Yr. CAGR % | 17.43 | 39.2 | 29.09 | 17.08 | 22.23 | |||||
Tangible Book Value, 5 Yr. CAGR % | -2.55 | 9.48 | -26.15 | 19.29 | -14.55 | |||||
Common Equity, 5 Yr. CAGR % | -2.41 | 21.58 | -24.61 | 9.77 | 1.75 | |||||
Cash From Operations, 5 Yr. CAGR % | 16.85 | 19.88 | 20.2 | 15.76 | 22.23 | |||||
Capital Expenditures, 5 Yr. CAGR % | 12.56 | 11.66 | 26.91 | 0.3 | -12.3 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 11.98 | 15.96 | 17.48 | 20.1 | 16.05 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 12.88 | 17.22 | 16.61 | 17.04 | 13.12 |
- Stock Market
- Equities
- INSM Stock
- Financials Insmed Incorporated
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition